Biologic Therapy

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.

Healio has compiled October’s most read news in asthma and allergy.

BOSTON — Physicians can take a deep dive into the current state of asthma care as the American College of Allergy, Asthma & Immunology opens its 2024 conference on Thursday, Oct. 24, with a full day dedicated to diagnosis and treatment.

Healio’s Women in Allergy explored potential risks women may face associated with cooking exposures.

For patients with rotator cuff tears, augmentation with a bioinductive collagen implant may yield positive outcomes with low rates of retears and improved tendon thickness, according to published results.

Risankizumab showed a significant improvement in psoriasis severity and quality of life in biologic-naïve patients and in those previously treated with other biologics, according to a study.

Patients with severe asthma and small airways disease did not respond as well to omalizumab treatment, according to a poster presented at the European Respiratory Society International Congress.

SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.

The American College of Rheumatology has applauded an FDA proposal to streamline the approval of interchangeable biosimilars, removing requirements for switching studies to determine their interchangeability with reference products.

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.